Synonym
AZD8926; AZD-8926; AZD 8926.
IUPAC/Chemical Name
(4-((5-fluoro-4-(1-(tetrahydro-2H-pyran-4-yl)-2-(trifluoromethyl)-1H-imidazol-5-yl)pyrimidin-2-yl)amino)phenyl)(4-methylpiperazin-1-yl)methanone
InChi Key
JKLMQKZMMRJQCK-UHFFFAOYSA-N
InChi Code
InChI=1S/C25H27F4N7O2/c1-34-8-10-35(11-9-34)22(37)16-2-4-17(5-3-16)32-24-31-14-19(26)21(33-24)20-15-30-23(25(27,28)29)36(20)18-6-12-38-13-7-18/h2-5,14-15,18H,6-13H2,1H3,(H,31,32,33)
SMILES Code
O=C(C1=CC=C(NC2=NC=C(F)C(C3=CN=C(C(F)(F)F)N3C4CCOCC4)=N2)C=C1)N5CCN(C)CC5
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related:
933785-68-3 (AZD8926 free base)
933784-48-6 (AZD8926 HCl salt).
Preparing Stock Solutions
The following data is based on the
product
molecular weight
533.53
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1. A Novel Scalable Process to the GSK3β Inhibitor AZD8926 Based on a Heterocyclic Ziegler Coupling
By Witt, Anette; Teodorovic, Peter; Linderberg, Mats; Johansson, Peter; Minidis, Anna
From Organic Process Research & Development (2013), 17(4), 672-678. | Language: English, Database: CAPLUS
2. A new combination of (a) an α-4-β-2-neuronal nicotinic agonist and (b) a glycogen synthase kinase 3 (GSK3) inhibitor
By Basun, Hans; Cox, Graham; Nordgren, Ingrid; Bencherif, Merouane
From PCT Int. Appl. (2009), WO 2009017455 A1 20090205. | Language: English, Database: CAPLUS
3. New therapeutic combination of an antipsychotic and a glycogen synthase kinase 3 (GSK3) inhibitor 958
By Basun, Hans; Cox, Graham; Nordgren, Ingrid
From PCT Int. Appl. (2009), WO 2009017453 A1 20090205. | Language: English, Database: CAPLUS
4. New therapeutic combination of a glycogen synthase kinase-3 (GSK3) inhibitor and an α7-nicotinic agonist
By Basun, Hans; Cox, Graham; Nordgren, Ingrid
rom PCT Int. Appl. (2009), WO 2009017454 A1 20090205. | Language: English, Database: CAPLUS
5. New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of Alzheimer's disease
y Andersson, Lars; Arzel, Erwan; Berg, Stefan; Burrows, Jeremy; Hellberg, Sven; Huerta, Fernando; Pedersen, Torben; Rein, Tobias; Rotticci, Didier; Staaf, Karin; et al
From PCT Int. Appl. (2007), WO 2007040440 A1 20070412. | Language: English, Database: CAPLUS
